An editorial publisher, not a clinic.

Doctor CJC-1295 is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295 (a long-acting GHRH analog also referenced in the literature as CJC-1295 with DAC, DAC:GRF, and the closely related non-DAC backbone modified GRF(1-29)). Editorial work consists of reading, summarizing, citing, and structurally organizing publicly available scientific publications, ClinicalTrials.gov records, FDA actions, and World Anti-Doping Agency documents.

The site is not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'doctor' prefix in the domain name is editorial framing — a position the publisher occupies relative to the literature, not a claim about the site's services. Read it in this dossier as 'chief engineer' rather than 'physician,' consistent with the engineering-spec frame the editorial design takes. The site does not offer consultations, prescriptions, examinations, diagnoses, or any other clinical service. There is no clinical staff, no clinical location, no clinical practice, and no clinical relationship of any kind between the site and any reader.

This distinction matters because the published CJC-1295 record sits squarely on the research-chemical side of the line. CJC-1295 is not approved for any human therapeutic indication. No legitimate clinician prescribes it as an approved drug. A site framing itself as a clinic for CJC-1295 would be misrepresenting both the compound and the regulatory architecture. We are a publisher; we describe what the published record says.

Every quantitative claim on this site cites a primary source — peer-reviewed publication, registered trial, FDA action, or WADA document. The full citation list lives on the References page with DOIs and stable identifiers. Outbound links are to primary sources only: PubMed, PMC, NIH, ClinicalTrials.gov, the FDA website, the WADA website, and the journals themselves.

When a claim sits in the research literature with limits — small sample size, single-cohort design, terminated trial, in vitro only, class-comparator extrapolation — those limits are stated. The CJC-1295 evidence base is unusually shallow for a peptide with this much downstream usage; the editorial framing is to make the shallowness visible rather than to paper over it.

No prescriptive language appears anywhere on the site. We describe what was studied or what regulators have said; we do not recommend doses or routes or protocols. Where a number appears, it is sourced and attributed.

Not a medical practice. Not a telehealth service. Not a compounding pharmacy. Not a research-chemical vendor. Not affiliated with any vendor, manufacturer, compounding pharmacy, telehealth provider, clinic, or commercial source of CJC-1295 or any related peptide. The site does not link to vendor pages and does not promote any commercial source. The Phase 1 disclaimer at the foot of every page reads: 'For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.'